<DOC>
	<DOCNO>NCT00615901</DOCNO>
	<brief_summary>CMF ( cyclophosphamide , methotrexate , fluorouracil ) use treat early stage breast cancer . The combination , three drug , use approximately 30 year treatment breast cancer , show safe effective . It usually give every 3 week . Doctors believe , base breast cancer trial , give type chemotherapy shorter amount time , every 2 week sooner , instead every 3 week , may better . The purpose study test safety drug , give every 2 week sooner , treat breast cancer . Other breast cancer chemotherapy regimens show beneficial drug give frequently .</brief_summary>
	<brief_title>Dose Dense Adjuvant CMF ( Cyclophosphamide , Methotrexate , Fluorouracil ) 14 10-11 Day Intervals Women With Early Stage Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Patients must histologically confirm adenocarcinoma breast confirm MSKCC within 3 month enrollment . Patients inflammatory breast cancer eligible study . Pathology assess standard fashion . Results HER2/neu , estrogen receptor , progesterone receptor require study entry . The patient Her2/neu overexpressing either immunohistochemistry FISH per hospital laboratory standard whether institutional outside laboratory . Patients must &gt; equal 18 year age Patients must Karnofsky score &gt; equal 80 Patients may receive hormonal therapy purpose chemoprevention must willing discontinue least 24 hour prior enrollment participate trial . Patients complete definitive breast surgery ( mastectomy breast conserving surgery ) Patients must ready begin therapy within 84 day final surgical procedure require treat primary tumor Patients must stage III Absolute neutrophil count ( ANC ) &gt; equal 1500/µL platelet count &gt; equal 100,000/µL Total bilirubin must &lt; equal 1.1 mg/dL within normal institutional limit outside MSKCC . Transaminases ( SGOT/AST and/or SGPT/ALT ) may &lt; equal 92.5 U/L &lt; equal 2.5 x institutional upper limit normal ( ULN ) alkaline phosphatase &lt; equal ULN , alkaline phosphatase may 4 x ULN transaminases &lt; equal ULN . Serum creatinine must within 0.61.3 mg/dL within normal institutional limit outside MSKCC . Patients must willing discontinue sex hormonal therapy e.g. , birth control pill , ovarian hormonal replacement therapy , etc. , prior enrollment . Women childbearing potential must willing consent use effective contraception treatment reasonable period thereafter . Patients must give write , informed consent indicate understanding willingness participate study . Brachytherapy lumpectomy permit . Stage IIIIV breast cancer Prior chemotherapy radiation therapy exclude except brachytherapy.Radiation patient protocol give , indicate , completion chemotherapy . Pregnant lactating patient Patients concurrently active second malignancy , adequately treat nonmelanoma skin cancer situ cervical cancer . Patients nonmammary malignancy must diseasefree least five year . Patients unstable angina , congestive heart failure , current use digitalis , betablockers , calcium blocker therapy congestive heart failure , arrhythmia require medical therapy , history myocardial infarction within 12 month . Patients psychiatric illness would prevent understanding nature investigational therapy comply protocol requirement . Patients concurrent medical condition , , judgment investigator , would make inappropriate candidate study enrollment Patients active , unresolved infection Patients know sensitivity E. coli derive protein , PEGfilgrastim , filgrastim , component product . Patients must Her 2/neu nonoverexpressing .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>cyclophosphamide</keyword>
	<keyword>methotrexate</keyword>
	<keyword>fluorouracil</keyword>
	<keyword>PEG-filgrastim</keyword>
</DOC>